Clinical Research Directory
Browse clinical research sites, groups, and studies.
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Sponsor: University of Alabama at Birmingham
Summary
Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients are at increased risk of graft versus host disease, and the infusion of a CD34 selected graft would reduce such a risk. The infusion of CD34 selected graft using CliniMACS plus is currently FDA FDA-approved indication for acute myeloid leukemia. However, the use of the Prodigy would streamline the processing, in terms of hands-off procedure, allowing to provision of this product to the patients without strains on the cell therapy lab team. This procedure has been demonstrated safe and effective in several single-center studies and is currently in advanced phase investigation in several studies for malignant and non-malignant conditions.
Official title: Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS
Key Details
Gender
All
Age Range
4 Weeks - 75 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-04-22
Completion Date
2029-12
Last Updated
2025-04-24
Healthy Volunteers
No
Interventions
Infusion of CD34 selected hematopoietic stem cells
CD34 stem cell isolation and infusion to reduce alloreactive complication of stem cell infusion
Locations (1)
University of Alabama at Birmingham
Birmingham, Alabama, United States